Oncolyn Induces Apoptosis of Cancer Cells, Causes Clinical … · 2014. 12. 11. · ONCOLYN CAUSES...
1
TELOMERASE ACTIVITY INHIBITION IN VARIOUS CANCER CELLS AFTER TREATMENT WITH ONCOLYN Concentration MCF-7 Hela SPC-A1 (mcg/ml) (Breast Cancer)(Cervix Cancer) (Lung Cancer) O D 0 1.726±0.12 1.817±0.11 1.683±0.09 24 hrs. 50 1.440±0.10 1.475±0.08 1.374±0.06 100 1.328±0.11 1.286±0.09 1.209±0.08 TELOMERASE ACITIVITY INHIBITION OF VARIOUS CELLS AFTER TREATMENT WITH ONCOLYN (50 mcg/ml) Incubation MCF-7 Hela SPC-Al time (hr) (Breast Cancer)(Cervix Cancer)(Lung Cancer) O D 0 1.726±0.12 1.817±0.1 1.683±0.09 24 1.440±0.10 1.475±0.08 1.374±0.06 48 1.215±0.08 1.304±0.09 1.196±0.08 Oncolyn Induces Apoptosis of Cancer Cells, Causes Clinical Remission of Solid Tumors, Ameliorates Neurodegeneration and Exhibits Radiation Protection Arthur H.K. DJang, M.D., Ph.D., M.P.H. 1 M. Bud Nelson, Ph.D., J.D., 1 Zhou Dian-Yuan, M.D., 2 Lai Zho-Sheng, M.S., 2 Bai Jiang M.D. Ph.D, 2 M. Edeas, M.D., Ph.D., 3 Mikhael Adams, N.D., 5 Alison F. Adams, D. Ac., 5 Sun Hui, M.D. 6 Wang Ai-Ping, M.D., 6 Zhang Yanshu, M.B.,Ph.D., 7 Sun Qing-Yu, M.D., 9 Ginnette Pelletier, N.D., 8 Lucy Lafontaine, N.D., 8 Peter Moscow, Ph.D., 10 Dimitrios Galaris, Ph.D., 4 Heather Murley, D.V.M., 10 Zhang Zhong-Li, DVM., 11 1 Santé International, Inc., Jamestown, New York, USA, 2 Southern Medical University, Guangzhou, China, 3 Hospital Antione Beclere, Paris, France, 4 University Ioannina, School of Medicine, Greece, 5 Renascent Integral Health Centre, Ontario, Canada, 6 School of Public Health, North China United University, Tangshan, China, 7 Tianjin Cancer Center and Medical University, Tianjin, China, 8 Private Practice, Montreal & Ottawa, Canada, 9 Private Practice, Dalian, China, 10 Private Practice, Louisville, KY & Ithaca, NY., 11 Tianjin Environmental Protection Institute, Tianjin, China Oncolyn ® is a formulated extract from three edible plants. More than ninety percent of its ingredients are flavonoids, polyphenols, proanthocyanidins, phenolic acid and saponins in synergistic combination with other natural plant ingredients including EGCG, which together exhibited effective antioxidant, anti-inflammatory, antineurodegeneration and other cytoprotective functions. It neutralized the oxidative damage of H2O2 to human lymphocytes, and ROS damage to Pleural fluid cytology Lung biopsy Inhibition of telomerase results in erosion of telomeres, and eventual cessation of cancer cell proliferation and apoptosis. AM control AM with Asbestos AM with Asbestos and Oncolyn Asbestos exposed lung Oncolyn treated lung after asbestos exposure Control lung AM with Silica Against DNA damage by asbestos of alveolar macrophages assessed by single cell gel electrophoresis isolated from Wistar rats. Oncolyn’s Protection of Lung’s Injury Against Asbestos Inhalation and Silica Exposure in Wistar Rats Oncolyn inhibited the telomerase 1,2,6 activity of various cancer cell lines and correlated with cancer cell apoptosis. In vitro, Oncolyn inhibited HIV replication. It markedly reduced p24 antigen expression 3 after 14 days post-infection. (Dr. Edeas group, Paris) In nude mouse, Oncolyn® was found to be very effective against implanted human cancer cells of lung, colon, liver and stomach origin for both prevention and therapy. Expression of FAS genes, a biomarker for apoptosis, was demonstrated by immunohistochemistry for both prevention and therapy groups. Subrenal capsule assay in mice showed Oncolyn caused reduction of implanted tumor fragments from patients with invasive breast carcinoma, rectal adenocarcinoma and squamous cell carcinoma of the lung. Oncolyn reduced the implanted carcinoma by itself, and synergistically with other chemotherapeutic agents such as cytoxan, 5FU and methotrexate, cisplatin and adriamycin. Oncolyn caused objective and subjective improvement of patients with different types of cancers (90%), some in clinical remission, in an in-patient setting, 90 days, in a large teaching hospital. Median survival of malignant diffuse thoracic mesothelioma is less than 6 months. From the time of definitive pathology diagnosis, approximately 90% of the patients are dead within a period of one year, in spite of combination therapy with surgery, radiation and chemotherapy. In 1999, we applied Oncolyn for one terminal pulmonary mesothelioma patient and achieved a clinical remission in 6 months. The patient is living and well and working full time as of October 2010. A terminal disseminated intraosseous lymphoma patient also achieved clinical remission in 6 months with Oncolyn therapy in July 1999. Patient finally passed away from pneumonia in March 2005. Another patient with Embryonal carcinoma of the testis with metastases to the liver and lung achieved a clinical remission in 6 months using Oncolyn, and fathered a healthy child now 11 yrs old and his wife gave birth to two additional healthy babies. (June 2010). Oncolyn has 5 patents (3 United States, 1 US provisional, 1 Canadian , 1 EU) and 2 International Trademarks. Supported in part by a grant from Santé International, USA Oncolyn's Function Against Human Stomach Cancer (7901 CA) in Nude Mouse Oncolyn's Function Against Human Liver Cancer (HepG-II) in Nude Mouse Oncolyn's Function Against Human Colon Cancer (LoVo) in nude mouse Oncolyn's Function Against Human Small Cell Lung Cancer (SPC-A1) in nude mouse FAS Immunohistochemistry FAS Immunohistochemistry Control Prevention Therapy Control Prevention Therapy Control Therapy Control Prevention Therapy Lymphoma Embryonal Carcinoma of Testes Oncolyn Protects Endothelium from OxLDH Injuries Control No Oncolyn Oncolyn 50 mcg/ml Oncolyn 100 mcg/ml Oncolyn 150 mcg/ml endothelial cells. Oncolyn further protected pulmonary macrophages and Wistar rats from inhalation injury by asbestos and silica. It also exhibited anti-radiation protection in mice and man. Oncolyn is highly inhibitory against various cancer cells in vitro. Cell cycle studies with flow cytometry, and morphological changes observed with electron microscopy demonstrated cancer cells showing various stages of apoptosis under the influence of Oncolyn. ONCOLYN CAUSES APOPTOSIS OF DIFFERENT CANCER CELLS (24 hrs. exposure, Oncolyn 25 mcgml) MCF-7 (breast cancer) SPC-A1 (lung cancer) Hela (cervix cancer) Control Treatment Control Treatment Control Treatment SRC ASSAY OF ONCOLYN VS INVASIVE DUCTAL CARCINOMA OF THE BREAST Comparison with Standard Chemotherapy Agent TS 0 TS 5 ΔTS Control 12.0 12.5 +0.5 CMF 11.35 11.3 -0.05 CMF + Oncolyn (L) 11.8 11.0 -0.08 CMF + Oncolyn (M) 12.6 9.7 -2.9 CMF + Oncolyn (H) 13.35 11.2 -2.15 Oncolyn (L) 12.0 10.5 -1.5 Oncolyn (M) 13.95 12.55 -1.4 Oncolyn (H) 11.9 9.95 -1.95 TMF 11.44 9.38 -2.06 CMF + TMF 13.4 12.0 -1.04 TMF + Oncolyn (M) 13.8 10.45 -3.35 TMF + Oncolyn (H) 12.56 11.06 -1.5 Invasive Ductal Carcinoma, 56F Invasive Ductal Carcinoma, 50F Invasive Ductal Carcinoma, 61F Tumor Explant in Mouse Tumor Explant in Mouse Tumor Explant in Mouse SUMMARY, CLINICAL APPLICIATION OF ONCOLYN Oncolyn® was used for the past 15 years for anti-cancer therapy and prevention (US Patent 6,168,795) principally in US and Canada. It was also used for patients in Europe and Asia (EU Patent 0979037) for different types of malignancies. It caused clinical improvement and cancer foci regression in pancreatic, lung, liver, stomach and colon cancer, detectable with tumor markers and different imaging devices. Oncolyn is compatible with surgery, radiation and chemotherapy. It effectuated a complete clinical remission in some cases of lymphoma, breast cancer, prostate cancer, embryonal carcinoma of the testis, colon cancer, liver cancer and disseminated mesothelioma. Oncolyn is synergestic with radiation and/or chemotherapy. It reduced leucopenia, infection and other complications. Oncolyn Delayed the Senescence of Mice and Extended the Life Span of Flies (M.domestica) and caused clinical Amelioration of Neurodegeneration Oncolyn's Influence on CNS SOD Activity of Musca domestica at 25 days Group SOD Activity Increase(%) (u/mg protein) χ±SD Control n=80 92.4 ± 28.0 79.8 Oncolyn n=80 166.2 ± 42.6 (Life span of house flies increased to 45 days vs control of 26 days) The effect of Oncolyn on the level of SOD, GSH-Px,NO, NOS in mice serum Groups \ mean N=20 SOD (u/ml) GSH-Px (u) NO (mmol/L) NOS (u) Control Group 173.23 ± 22.94 1730.74 ± 15.2 39.2 ± 3.17 18.60 ± 0.77 Aging Group 143.19 ± 13.8# 105.81 ± 13.2# 49. 19 ± 4.92# 25.29 ± 2. 73# Oncolyn Group 190.31 ± 30.97# 163.15 ± 25.9* 43. 36 ± 4.83* 21.73 ± 2.81* # denotes a significant difference relative to the control values p< 0.05 * denotes a significant difference relative to the aging values p< 0.05 Effect of Oncolyn on the Content of Dopamine(DA), Noradrenalin(NE), MDA in Brain Tissue of Aging Mice(Ng/g) # denotes a significant difference relative to the control values p<0.05 * denotes a significant difference relative to the aging values p<0.05 The content of DA and NE in aging group is lower than the control group and the difference is significant. When aging mice were treated Oncolyn, the content of DA and NE increased, especially the NE concentration. Groups DA NE MDA (mmol/mg pro) Control group 1.769±0.129 0.0743±0.025 0.614±0.18 Aging group 1.344±0.127# 0.0145±0.0012# 1.226±0.39# Oncolyn group 1.761±0.135* 0.1490±0.027* 0.630±0.21* Oncolyn extended the life expectancy of Musca domestica and Drosophila melanogaster. Oncolyn further delayed the senescence of mice as verified by brain biochemistry and mice behavior pattern. Acknowledgements: LouAnn Malta - Data Management / Russ Morris - Poster Design Alba, Italy, June 2012 CANINE MAMMARY CANCER Contributed by: Heather Murley, DVM, Ithaca, NY Mammary cancer is the most common malignant tumor in dogs. In July 16, 2004, Fiona, a mixed female dog was found to have a large ulcerated breast tumor and was severely anemic. Surgery removed a 1.5 pound of tumor, ductular papillary cystadenocarcinoma, with lymph node metastases. Fiona’s pre-op weight was only thirty (30) pounds. After surgery, she was placed on Oncolyn, Co Q10, antibiotics and other support therapies. She recovered very quickly. As of July 2005, Fiona has gained ten (10) more pounds and retaining a healthy weight of forty-five (45) pounds (03/2008). Our group felt that Oncolyn was the major contributing factor for this process. She died from old age Feb 2009. Contributed by: Peter Moscow, Ph.D., Louisville, Kentucky, USA. Butch, a large black dog was examined in August, 2001. His diagnoses was terminal cancer of the liver, adenocarcinoma with ascites. The tumor was large and palpable. At the time of diagnosis he had almost stopped eating and was wasting rapidly. The veterinarian had advised that he should be put down immediately due to his age (11.5 years) and condition. The owner refused to do this and decided to try an alternative approach. Treatment with Oncolyn was started along with supportive therapy. Within days there were many positive responses. He began walking every day for a number of miles and had an excellent appetite for natural food. He passed away peacefully in 2003 at 14 years of age. Aside from becoming thinner in his last 6 months he displayed no signs of any illness. Treatment response to Oncolyn at our Clinic for human colon cancer and renal carcinoma has also shown impressive favorable results. CANINE WITH ADENOCARCINOMA OF THE LIVER, TERMINAL STAGE Concomitantly Oncolyn also caused amelioration of rheumatoid and osteoarthritis and produced a feeling of wellness in patients with various chronic debilitating conditions including COPD. References 1. Lan, Lin, et al – Clinical Observation of Oncolyn’s Effectiveness for Advanced Malignancies of the GI Tract. Modern Gastroenterology (Xiandia XioXua) 12: 110-111, 2001. 2. I. Naasani, et al – Blocking Telomerase by Dietray Polyphenols Is a Major Mechanism for Limiting the Growth of Human Cancer Cells and in Vivo, Cancer Research 63 : 824-830, 2003. 3. Zhang, Wei, et.al - Influence of Oncolyn on activities of ATPase and the expression of Neurotrophic factors in aging mice., Journal of Hygiene Research (China), 36: 164-166, 2007. 4. Ehmhoefer D, et al, - EGCG redirects amyloidogenic polypeptides into unstructured off-pathway oligomers , Nature, Structural and Molecular Biology, 15: 568-566, 2008. 5. Reinberg, S, - Green Tea Antioxidant May Help Prevent Alzheimer’s, ABC News, May 30, 2009. 6. Barrenco Quintana, JL, et al, - Parkinson’s Disease and tea, a quantitative review. Journal of the American College of Nutrition. 28: 1-6, 2009. 7. Weinreb, O, Mandel ,S, Amit, T, Youdim, MB, - Green Tea may be protective against Parkinson’s and Alzheimer’s diseases by acting as metal chelation and antioxidants., J. Nutr. Biochem, 509-16, Sept 2004. 8. Bastianetto, S, Yao, Z, Papadoloulos, V & Quinrion, R. – Neuroprotective effects of Green & Black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Europ J. Neuroscience 23: 55-64, 2006. 9. Sun, QY and DJang, A.H.K. – Seminar on Aging and Neurodegeneration, Dalian, China, July 10, 2010. 10. Previc, F.H. – Dopamine and the origin of human intelligence, Brain and Cognition, 41: 279-350, 1999. 11. Emerit I, et.al. , Department of Genetics, CNRS, Paris, France. Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Radiat Res. 1995 Nov; 144(2):198-205. 12. Hosseinimehr S J, et. al., Radioprotective effects of Hawthorn against genotoxicity induced by gamma irradiation in human blood lymphocytes, Radiat Environ Biophys. 2009 Feb; 48(1):95-8. 13. Chen, WC, et al., Protective effects of Gynostemma pentaphyllum in gamma-irradiated mice, AJCM, 1996:24(1):83-92. 14. Protective activity of different concentration of tea polyphenols and its major compound EGCG against whole body irradiation-induced injury in mice, Zhongguo Zhong Yao Za Zhi, Guo S, et.al., May 2010, p1328-1331 15. Parshad R; Sanford K K, et.al, Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells., Anticancer Res. 1998 Sep-Oct; 18 (5A): 3263-6. In aging mice, the activities of ATPase in the brain and the protein expression of nerve growth factor (NGF), and brain- derived neurotrophic (BDNF) in hippocampus showed significant decrease. Oncolyn administration reversed the trend of decrease in mice (Zhang). Clinical observation (Since 2005) of senior population taking Oncolyn showed a reduction of incidence and amelioration of neurodegenerative disease such as Parkinson and Alzheimer. This project is in progress. (Sun, Q.Y., DJang, A.H.K. – Seminar on Aging and Neurogeneration, Dalian, China 7/2010) Direct measurement of free radicals’ scavenging function of Oncolyn Extract for 0 2 superoxide anion radical produced by xanthine-xanthine oxidase system and the hydroxyl radical (OH) generated by Fenton reaction was demonstrated. This is the plausible molecular biological basis for Oncolyn’s anti-mutation, and anti-aging functions. Group Dose WBC/mm Change Micro- (mg/kg/day) * SD (%) (%) nucleus Control 7000±550 2.3 Model Co 300r 1910±450 -72.7 17.6 Irradiated with Co-60 Oncolyn 300X10 4110±4331 +115.2 4.0 (plant extract) Oncolyn 400X10 4500±4701 +135.2 2.1 (plant extract) Eight human volunteers 25-30 yrs of age gave peripheral blood samples then ingested one gm of Oncolyn each. At 1 hour and 3 hours post ingestion, blood samples were taken again. All samples were subjected to 1.2 Gy γ-radiation. Portion of the blood sample were used for micronucleus and comet assay. The baseline is the blood sample did not receive γ-radiation. Radiation Protection in Mice and Man 11-15 Radiation Protection Effect on Leucocytes and Frequency of Micronucleus in Mice Irradiated with 60 Co. (N=10) Frequency of Comet cells (%) in different categories Human Volunteers Baseline γ ray γ+ ray + oncolyn γ ray + oncolyn number comet % irradiated 1 hour 3 hours 1 5.2 ±1.1 62.57±15.44 40.12±8.57 22.66±6.12 2 4.8 ±0.92 58.79±11.09 41.23±9.66 23.58±5.72 3 5.7±1.1 59.87±10.38 38.64±7.38 19.67±8.97 4 5.7±1.0 61.72±15.44 42.71±9.37 25.41±6.77 5 6.2±1.3 68.99±17.78 46.35±9.16 27.32±5.64 6 5.0±1.3 54.12±10.23 34.72±6.97 18.67±5.12 7 5.2±1.4 56.38±8.67 39.66±7.82 19.68±7.53 8 5.8±1.5 61.46±14.55 40.19±9.68 20.18±3.22 Frequency of Micronucleus (0/00) in different categories Human Volunteers Baseline γ ray γ ray+ γ ray+ Number micronucleus (0/00) irradiated + oncolyn 1h + oncolyn 3h 1 1.3±0.1 13.3±0.3 9.0±0.7 6.3±0.2 2 1.3±0.1 12.3±0.6 8.0±0.6 6.7±0.3 3 1.7±0.1 10.9±0.4 8.7±0.5 5.7±0.3 4 1.3±0.1 13.6±0.8 10.7±0.5 6.7±0.2 5 2.0±0.0 13.7±0.7 10.7±0.6 6.3±0.2 6 1.3±0.1 14.7±0.7 10.3±0.7 7.0±0.0 7 1.0±0.0 15.3±0.5 12.0±0.2 9.3±0.3 8 1.3±0.1 13.5±0.8 10.3±0.4 7.0±0.4 The above data further verified clinical observation that Oncolyn ameliorates the injurious effect of radiation and chemotherapy for patients with various malignancies. Oncolyn is effective for preventing, reducing and treating radiation induced injuries.
Transcript of Oncolyn Induces Apoptosis of Cancer Cells, Causes Clinical … · 2014. 12. 11. · ONCOLYN CAUSES...
TELOMERASE ACTIVITY INHIBITION IN VARIOUS CANCER CELLS AFTER TREATMENT WITH ONCOLYN
Concentration MCF-7 Hela SPC-A1(mcg/ml) (Breast Cancer)(Cervix Cancer) (Lung Cancer)
O D 0 1.726±0.12 1.817±0.11 1.683±0.09
24 hrs. 50 1.440±0.10 1.475±0.08 1.374±0.06
100 1.328±0.11 1.286±0.09 1.209±0.08
TELOMERASE ACITIVITY INHIBITION OF VARIOUS CELLS AFTER TREATMENT WITH ONCOLYN (50 mcg/ml)
Incubation MCF-7 Hela SPC-Altime (hr) (Breast Cancer)(Cervix Cancer)(Lung Cancer)
O D 0 1.726±0.12 1.817±0.1 1.683±0.09
24 1.440±0.10 1.475±0.08 1.374±0.06
48 1.215±0.08 1.304±0.09 1.196±0.08
Oncolyn Induces Apoptosis of Cancer Cells, Causes Clinical Remission of Solid Tumors, Ameliorates Neurodegeneration and Exhibits Radiation Protection
Arthur H.K. DJang, M.D., Ph.D., M.P.H.1
M. Bud Nelson, Ph.D., J.D.,1 Zhou Dian-Yuan, M.D.,2 Lai Zho-Sheng, M.S.,2 Bai Jiang M.D. Ph.D,2 M. Edeas, M.D., Ph.D.,3 Mikhael Adams, N.D.,5 Alison F. Adams, D. Ac.,5 Sun Hui, M.D.6 Wang Ai-Ping, M.D.,6
Zhang Yanshu, M.B.,Ph.D.,7 Sun Qing-Yu, M.D.,9 Ginnette Pelletier, N.D.,8 Lucy Lafontaine, N.D.,8 Peter Moscow, Ph.D.,10 Dimitrios Galaris, Ph.D.,4 Heather Murley, D.V.M.,10 Zhang Zhong-Li, DVM.,11
1Santé International, Inc., Jamestown, New York, USA, 2Southern Medical University, Guangzhou, China, 3Hospital Antione Beclere, Paris, France, 4University Ioannina, School of Medicine, Greece, 5Renascent Integral Health Centre, Ontario, Canada, 6School of Public Health, North China United University,Tangshan, China, 7Tianjin Cancer Center and Medical University, Tianjin, China, 8Private Practice, Montreal & Ottawa, Canada, 9Private Practice, Dalian, China, 10Private Practice, Louisville, KY & Ithaca, NY., 11Tianjin Environmental Protection Institute, Tianjin, China
Oncolyn® is a formulated extract from three edible plants. More than ninety percent of its ingredients are flavonoids,polyphenols, proanthocyanidins, phenolic acid and saponins in synergistic combination with other natural plant ingredientsincluding EGCG, which together exhibited effective antioxidant, anti-inflammatory, antineurodegeneration and other cytoprotective functions. It neutralized the oxidative damage of H2O2 to human lymphocytes, and ROS damage to
Pleural fluid cytology Lung biopsy
Inhibition of telomerase results in erosion of telomeres, and eventual cessation of cancer cell proliferation and apoptosis.
AM controlAM with Asbestos
AM with Asbestos and Oncolyn
Asbestos exposed lung
Oncolyn treated lung after asbestos
exposureControl lungAM with SilicaAgainst DNA damage
by asbestos of alveolar macrophages assessed by single cell gel electrophoresis isolated from Wistar rats.
Oncolyn’s Protection of Lung’s Injury Against Asbestos Inhalation and Silica Exposure in Wistar Rats
Oncolyn inhibited the telomerase1,2,6 activity of various cancer cell lines and correlated with cancer cell apoptosis.
In vitro, Oncolyn inhibited HIV replication. It markedly reduced p24 antigen expression3 after 14 days post-infection. (Dr. Edeas group, Paris)
In nude mouse, Oncolyn® was found to be very effective against implanted human cancer cells of lung, colon, liver and stomach origin for both prevention and therapy. Expression of FAS genes, a biomarker for apoptosis, was demonstrated by immunohistochemistry for both prevention and therapy groups. Subrenal capsule assay in mice showed Oncolyn caused reduction of implanted tumor fragments from patients with invasive breast carcinoma, rectaladenocarcinoma and squamous cell carcinoma of the lung. Oncolyn reduced the implanted carcinoma by itself, and synergistically with other chemotherapeutic agents such as cytoxan, 5FU and methotrexate, cisplatin and adriamycin.Oncolyn caused objective and subjective improvement of patients with different types of cancers (90%), some in clinical remission, in an in-patient setting, 90 days, in a large teaching hospital.
Median survival of malignant diffuse thoracic mesothelioma is less than 6 months. From the time of definitive pathology diagnosis, approximately 90% of the patients are dead within a period of one year, in spite of combination therapy with surgery, radiation and chemotherapy. In 1999, we applied Oncolyn for one terminal pulmonary mesothelioma patient and achieved a clinical remission in 6 months. The patient is living and well and working full time as of October 2010. A terminal disseminated intraosseous lymphoma patient also achieved clinical remission in 6 months with Oncolyn therapy in July 1999. Patient finally passed away from pneumonia in March 2005. Another patient with Embryonal carcinoma of the testis with metastases to the liver and lung achieved a clinical remission in 6 months using Oncolyn, and fathered a healthy child now 11 yrs old and his wife gave birth to two additional healthy babies. (June 2010).
Oncolyn has 5 patents (3 United States, 1 US provisional, 1 Canadian , 1 EU) and 2 International Trademarks. Supported in part by a grant from Santé International, USA
Oncolyn's FunctionAgainst HumanStomach Cancer
(7901 CA)in Nude Mouse
Oncolyn's FunctionAgainst Human
Liver Cancer(HepG-II)
in Nude Mouse
Oncolyn's FunctionAgainst HumanColon Cancer
(LoVo)in nude mouse
Oncolyn's Function Against HumanSmall Cell Lung Cancer(SPC-A1) in nude mouse
FASImmunohistochemistry
FASImmunohistochemistry
Control
Prevention
Therapy
Control
Prevention
Therapy
Control
Therapy
Control
Prevention
Therapy
Lymphoma EmbryonalCarcinoma of Testes
Oncolyn Protects Endothelium from OxLDH Injuries
Control No Oncolyn Oncolyn 50 mcg/ml Oncolyn 100 mcg/ml Oncolyn 150 mcg/ml
endothelial cells.Oncolyn further protected pulmonary macrophages and Wistar rats from inhalation injury by asbestos and silica. It also exhibited anti-radiation protection in mice and man. Oncolyn is highly inhibitory against various cancer cells in vitro. Cell cycle studies with flow cytometry, and morphological changes observed with electron microscopy demonstrated cancer cells showing various stages of apoptosis under the influence of Oncolyn.
ONCOLYN CAUSES APOPTOSIS OF DIFFERENT CANCER CELLS (24 hrs. exposure, Oncolyn 25 mcgml)
MCF-7 (breast cancer) SPC-A1 (lung cancer) Hela (cervix cancer)Control Treatment Control Treatment Control Treatment
SRC ASSAY OF ONCOLYN VS INVASIVE DUCTAL CARCINOMA OF THE BREASTComparison with Standard Chemotherapy
Agent TS0 TS5 ΔTS
Control 12.0 12.5 +0.5CMF 11.35 11.3 -0.05CMF + Oncolyn (L) 11.8 11.0 -0.08CMF + Oncolyn (M) 12.6 9.7 -2.9CMF + Oncolyn (H) 13.35 11.2 -2.15Oncolyn (L) 12.0 10.5 -1.5Oncolyn (M) 13.95 12.55 -1.4Oncolyn (H) 11.9 9.95 -1.95TMF 11.44 9.38 -2.06CMF + TMF 13.4 12.0 -1.04TMF + Oncolyn (M) 13.8 10.45 -3.35TMF + Oncolyn (H) 12.56 11.06 -1.5
Invasive Ductal Carcinoma, 56F Invasive Ductal Carcinoma, 50F Invasive Ductal Carcinoma, 61F
Tumor Explant in Mouse Tumor Explant in Mouse Tumor Explant in Mouse
SUMMARY, CLINICAL APPLICIATION OF ONCOLYNOncolyn® was used for the past 15 years for anti-cancer therapy and prevention (US Patent 6,168,795) principally in US and Canada. It was also used for patients in Europe and Asia (EU Patent 0979037) for different types of malignancies. It caused clinical improvement and cancer foci regression in pancreatic, lung, liver, stomach and colon cancer, detectable with tumor markers and different imaging devices. Oncolyn is compatible with surgery, radiation and chemotherapy. It effectuated a complete clinical remission in some cases of lymphoma, breast cancer, prostate cancer, embryonal carcinoma of the testis, colon cancer, liver cancer and disseminated mesothelioma. Oncolyn is synergestic with radiation and/or chemotherapy. It reduced leucopenia, infection and other complications.
Oncolyn Delayed the Senescence of Mice and Extended the Life Span of Flies (M.domestica) and caused clinical Amelioration of Neurodegeneration
Oncolyn's Influence on CNS SOD Activity of Musca domestica at 25 days
Group SOD Activity Increase(%)(u/mg protein) χ±SD
Control n=80 92.4 ± 28.0 79.8
Oncolyn n=80 166.2 ± 42.6
(Life span of house flies increased to 45 days vs control of 26 days)
The effect of Oncolyn on the level of SOD, GSH-Px,NO, NOS in mice serum
Groups \ mean N=20 SOD (u/ml) GSH-Px (u) NO (mmol/L) NOS (u)Control Group 173.23 ± 22.94 1730.74 ± 15.2 39.2 ± 3.17 18.60 ± 0.77Aging Group 143.19 ± 13.8# 105.81 ± 13.2# 49. 19 ± 4.92# 25.29 ± 2. 73#Oncolyn Group 190.31 ± 30.97# 163.15 ± 25.9* 43. 36 ± 4.83* 21.73 ± 2.81*
# denotes a significant difference relative to the control values p< 0.05* denotes a significant difference relative to the aging values p< 0.05
Effect of Oncolyn on the Content of Dopamine(DA), Noradrenalin(NE), MDA in Brain Tissue of Aging Mice(Ng/g)
# denotes a significant difference relative to the control values p<0.05* denotes a significant difference relative to the aging values p<0.05The content of DA and NE in aging group is lower than the control group and the difference is significant. When aging mice were treated Oncolyn, the content of DA and NE increased, especially the NE concentration.
Groups DA NE MDA (mmol/mg pro)Control group 1.769±0.129 0.0743±0.025 0.614±0.18Aging group 1.344±0.127# 0.0145±0.0012# 1.226±0.39#Oncolyn group 1.761±0.135* 0.1490±0.027* 0.630±0.21*
Oncolyn extended the life expectancy ofMusca domestica and Drosophilamelanogaster.Oncolyn further delayed the senescence of mice as verified by brain biochemistry and mice behavior pattern.
Acknowledgements: LouAnn Malta - Data Management / Russ Morris - Poster Design Alba, Italy, June 2012
CANINE MAMMARY CANCER
Contributed by: Heather Murley, DVM, Ithaca, NYMammary cancer is the most common malignant tumor in dogs. In July 16, 2004, Fiona, a mixed female dog was found to have a large ulcerated breast tumor and was severely anemic.
Surgery removed a 1.5 pound of tumor, ductular papillary cystadenocarcinoma, with lymph node metastases. Fiona’s pre-op weight was only thirty (30) pounds. After surgery, she was placed on Oncolyn, Co Q10, antibiotics and other support therapies. She recovered very quickly.
As of July 2005, Fiona has gained ten (10) more pounds and retaining a healthy weight of forty-five (45) pounds (03/2008). Our group felt that Oncolyn was the major contributing factor for this process. She died from old age Feb 2009.
Contributed by: Peter Moscow, Ph.D., Louisville, Kentucky, USA. Butch, a large black dog was examined in August, 2001. His diagnoses was terminal cancer of the liver, adenocarcinoma with ascites. The tumor was large and palpable. At the time of diagnosis he had almost stopped eating and was wasting rapidly. The veterinarian had advised that he should be put down immediately due to his age (11.5 years) and condition. The owner refused to do this and decided to try an alternative approach.
Treatment with Oncolyn was started along with supportive therapy. Within days there were many positive responses. He began walking every day for a number of miles and had an excellent appetite for natural food. He passed away peacefully in 2003 at 14 years of age. Aside from becoming thinner in his last 6 months he displayed no signs of any illness.
Treatment response to Oncolyn at our Clinic for human colon cancer and renal carcinoma has also shown impressive favorable results.
CANINE WITH ADENOCARCINOMA OF THE LIVER, TERMINAL STAGE
Concomitantly Oncolyn also caused amelioration of rheumatoid and osteoarthritis and produced a feeling of wellness in patients with various chronic debilitating conditions including COPD.
References1. Lan, Lin, et al – Clinical Observation of Oncolyn’s Effectiveness for Advanced Malignancies of the GI Tract. Modern
Gastroenterology (Xiandia XioXua) 12: 110-111, 2001.2. I. Naasani, et al – Blocking Telomerase by Dietray Polyphenols Is a Major Mechanism for Limiting the Growth of
Human Cancer Cells and in Vivo, Cancer Research 63 : 824-830, 2003.3. Zhang, Wei, et.al - Influence of Oncolyn on activities of ATPase and the expression of Neurotrophic factors in aging
mice., Journal of Hygiene Research (China), 36: 164-166, 2007.4. Ehmhoefer D, et al, - EGCG redirects amyloidogenic polypeptides into unstructured off-pathway oligomers , Nature,
Structural and Molecular Biology, 15: 568-566, 2008.
5. Reinberg, S, - Green Tea Antioxidant May Help Prevent Alzheimer’s, ABC News, May 30, 2009.6. Barrenco Quintana, JL, et al, - Parkinson’s Disease and tea, a quantitative review. Journal of the American College of Nutrition. 28: 1-6, 2009. 7. Weinreb, O, Mandel ,S, Amit, T, Youdim, MB, - Green Tea may be protective against Parkinson’s and Alzheimer’s diseases by acting as metal chelation and antioxidants., J. Nutr. Biochem, 509-16, Sept 2004.8. Bastianetto, S, Yao, Z, Papadoloulos, V & Quinrion, R. – Neuroprotective effects of Green & Black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Europ J. Neuroscience 23: 55-64, 2006.9. Sun, QY and DJang, A.H.K. – Seminar on Aging and Neurodegeneration, Dalian, China, July 10, 2010. 10. Previc, F.H. – Dopamine and the origin of human intelligence, Brain and Cognition, 41: 279-350, 1999.11. Emerit I, et.al. , Department of Genetics, CNRS, Paris, France. Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Radiat Res. 1995 Nov; 144(2):198-205.12. Hosseinimehr S J, et. al., Radioprotective effects of Hawthorn against genotoxicity induced by gamma irradiation in human blood lymphocytes, Radiat Environ Biophys. 2009 Feb; 48(1):95-8.13. Chen, WC, et al., Protective effects of Gynostemma pentaphyllum in gamma-irradiated mice, AJCM, 1996:24(1):83-92.14. Protective activity of different concentration of tea polyphenols and its major compound EGCG against whole body irradiation-induced injury in mice, Zhongguo Zhong Yao Za Zhi, Guo S, et.al., May 2010, p1328-133115. Parshad R; Sanford K K, et.al, Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells., Anticancer Res. 1998 Sep-Oct; 18 (5A): 3263-6.
In aging mice, the activities of ATPase in the brain and the protein expression of nerve growth factor (NGF), and brain-derived neurotrophic (BDNF) in hippocampus showed significant decrease. Oncolyn administration reversed the trend of decrease in mice (Zhang). Clinical observation (Since 2005) of senior population taking Oncolyn showed a reduction of incidence and amelioration of neurodegenerative disease such as Parkinson and Alzheimer. This project is in progress. (Sun, Q.Y., DJang, A.H.K. – Seminar on Aging and Neurogeneration, Dalian, China 7/2010)
Direct measurement of free radicals’ scavenging function of Oncolyn Extract for 02 superoxideanion radical produced by xanthine-xanthine oxidase system and the hydroxyl radical (OH) generated by Fenton reaction was demonstrated. This is the plausible molecular biological basis for Oncolyn’s anti-mutation, and anti-aging functions.
Group Dose WBC/mm Change Micro-(mg/kg/day) * SD (%) (%) nucleus
Control 7000±550 2.3
Model Co 300r 1910±450 -72.7 17.6Irradiated
with Co-60
Oncolyn 300X10 4110±4331 +115.2 4.0(plant
extract)
Oncolyn 400X10 4500±4701 +135.2 2.1(plant
extract)
Eight human volunteers 25-30 yrs of age gave peripheral blood samples then ingested one gm of Oncolyneach. At 1 hour and 3 hours post ingestion, blood samples were taken again. All samples were subjected to 1.2 Gy γ-radiation. Portion of the blood sample were used for micronucleus and comet assay.
The baseline is the blood sample did not receive γ-radiation.
Radiation Protection in Mice and Man 11-15
Radiation Protection
Effect on Leucocytes and Frequency of Micronucleus in Mice Irradiated with 60Co.
(N=10)
Frequency of Comet cells (%) in different categories
Human Volunteers Baseline γ ray γ+ ray + oncolyn γ ray + oncolyn number comet % irradiated 1 hour 3 hours 1 5.2 ±1.1 62.57±15.44 40.12±8.57 22.66±6.122 4.8 ±0.92 58.79±11.09 41.23±9.66 23.58±5.723 5.7±1.1 59.87±10.38 38.64±7.38 19.67±8.974 5.7±1.0 61.72±15.44 42.71±9.37 25.41±6.775 6.2±1.3 68.99±17.78 46.35±9.16 27.32±5.646 5.0±1.3 54.12±10.23 34.72±6.97 18.67±5.127 5.2±1.4 56.38±8.67 39.66±7.82 19.68±7.538 5.8±1.5 61.46±14.55 40.19±9.68 20.18±3.22
Frequency of Micronucleus (0/00) in different categories
Human Volunteers Baseline γ ray γ ray+ γ ray+Number micronucleus (0/00) irradiated + oncolyn 1h + oncolyn 3h1 1.3±0.1 13.3±0.3 9.0±0.7 6.3±0.22 1.3±0.1 12.3±0.6 8.0±0.6 6.7±0.33 1.7±0.1 10.9±0.4 8.7±0.5 5.7±0.34 1.3±0.1 13.6±0.8 10.7±0.5 6.7±0.25 2.0±0.0 13.7±0.7 10.7±0.6 6.3±0.26 1.3±0.1 14.7±0.7 10.3±0.7 7.0±0.07 1.0±0.0 15.3±0.5 12.0±0.2 9.3±0.38 1.3±0.1 13.5±0.8 10.3±0.4 7.0±0.4
The above data further verified clinical observation that Oncolyn ameliorates the injurious effect of radiation and chemotherapy for patients with various malignancies. Oncolyn is effective for preventing, reducing and treating radiation induced injuries.
![Prohibitin (PHB) inhibits apoptosis in rat granulosa cells ...apoptosis of granulosa cells (GCs) during follicular growth and development [1, 2]. Ovarian GCs play an important physiological](https://static.fdocuments.in/doc/165x107/5f84f4a5739a256f3f64c746/prohibitin-phb-inhibits-apoptosis-in-rat-granulosa-cells-apoptosis-of-granulosa.jpg)
